706791-83-5

Basic information

• Product Name: 3-AMINO-5-BROMOBENZOATE
• Synonyms: 3-AMINO-5-BROMOBENZOATE;Methyl 3-Amino-5-bromobenzoate
• CAS NO: 706791-83-5
• Molecular Formula: C₈H₈BrNO₂
• Molecular Weight: 230.07
• Mol File: 706791-83-5.mol

Chemical Properties

• Melting Point: 83-88℃
• Boiling Point: 332.308 °C at 760 mmHg
• Flash Point: 154.775 °C
• Appearance: /
• Density: 1.578 g/cm³
• Storage Temp.: 2-8°C(protect from light)
• PKA: 2.38±0.10(Predicted)
• CAS DataBase Reference: 3-AMINO-5-BROMOBENZOATE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-AMINO-5-BROMOBENZOATE(706791-83-5)
• EPA Substance Registry System: 3-AMINO-5-BROMOBENZOATE(706791-83-5)

Safety Data

• Hazardous Substances Data: 706791-83-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3-AMINO-5-BROMOBENZOATE is used as an intermediate in organic synthesis for the production of various pharmaceuticals. Its unique structure allows it to be a key component in the development of new drugs and treatments.
Used in Agrochemical Industry:
3-AMINO-5-BROMOBENZOATE is also used as an intermediate in the synthesis of agrochemicals, contributing to the development of effective pesticides and other agricultural products.
Used in Antimicrobial Applications:
Due to its antimicrobial and antifungal properties, 3-AMINO-5-BROMOBENZOATE is used as an active ingredient in the development of new drugs and treatments for infections caused by bacteria and fungi.
Used in Drug Delivery Systems:
3-AMINO-5-BROMOBENZOATE can be incorporated into drug delivery systems to improve the efficacy and bioavailability of pharmaceuticals, particularly in the context of targeted therapies and controlled release formulations.

Upstream product

• 6307-87-5 methyl 3-bromo-5-nitrobenzoate 
• 618-95-1 methyl 3-nitrobenzoate 
• 67-56-1 methanol 
• 42237-85-4 3-amino-5-bromobenzoic acid 
• 6307-83-1 3-bromo-5-nitro-benzoic acid 
• 121-92-6 3-nitrobenzoic acid 

Downstream Products

• 706791-80-2 3-bromo-5-(4-chlorobutanoylamino)benzoic acid methyl ester 
• 1188322-84-0 methyl 3-bromo-5-(thiophene-2-carboxamido)benzoate 
• 1188322-86-2 methyl 3-bromo-5-[2-(thiophen-2-yl)acetamido]benzoate 
• 60912-61-0 methyl 3-bromo-5-acetylaminobenzoate 
• 1188322-78-2 methyl 3-bromo-5-benzamidobenzoate 
• 1188322-88-4 methyl 3-bromo-5-(2-phenoxyacetamido)benzoate 
• 1188322-80-6 methyl 3-bromo-5-(2-methoxybenzamido)benzoate 
• 1188322-76-0 methyl 3-bromo-5-(2-phenylacetamido)benzoate 
• 1188322-82-8 methyl 3-bromo-5-(2,6-dimethoxybenzamido)benzoate 
• 1268704-01-3 methyl 3-(nonylamino)-5-bromobenzoate 
• 1268704-11-5 3-(N-nonyl-N-benzoylamino)-5-bromo-N'-methylbenzanilide 
• 1268704-12-6 3-(N-nonyl-N-benzoylamino)-5-(2'-(5',2''-bithienyl))-N'-methylbenzanilide 
• 1268704-13-7 3-(N-nonyl-N-benzoylamino)-5-(2'-(5',2'',5'',2'''-terthienyl))-N'-methylbenzanilide 
• 1268704-03-5 methyl 3-(nonylamino)-5-(2'-(5',2''-bithienyl))benzoate 

Relevant articles and documents

Design, synthesis and evaluation of 3-amide-5-aryl benzoic acid derivatives as novel P2Y14R antagonists with potential high efficiency against acute gouty arthritis

P2Y14 nucleotide receptor plays important roles in series of physiological and pathologic events especially associated with immune and inflammation. Based on the 3-amide benzoic acid scaffold reported by our group previously, a series of 5-aryl-3-amide benzoic acid derivatives were designed as novel P2Y14 antagonists with improved pharmacokinetic properties. Among which compound 11m showed most potent P2Y14 antagonizing activity with an IC50 value of 2.18 nM, furnishing greatly improved water solubility and bioavailability compared with PPTN. In MSU-induced acute gouty arthritis model in mice, 11m exerted promising in vivo efficacy in alleviating mice paw swelling and inflammatory infiltration. Mechanistically, compound 11m notably blocked pyroptosis of macrophages through inhibiting NLRP3 inflammasome activation. This work may contribute to the identification of potential therapeutic agents to intervene in acute gouty arthritis.

Light and chemically driven molecular machines showing a unidirectional four-state switching cycle

The imitation of macroscopic movements at the molecular level is a key step in the development of nanomachines. The challenge is the synthesis of molecules that are able to transform external stimuli into a direction-controlled mechanical movement. The more complex such motion sequences are, the more difficult is the construction of the corresponding nanomachine. Here, we present a system that demonstrates a unidirectional, four-state switching cycle that bears similar characteristics to the arm movements of a human breaststroke swimmer. Like the latter, the molecules have a torso and two arms. The arms consist of bipyridine units and can be folded and stretched by addition and removal of copper ions. The unidirectional rotation of the arms is achieved by light-induced switching of an azo unit.

MACROCYCLIC RIP2-KINASE INHIBITORS

The present invention relates to macrocyclic compounds and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of RIP2-kinase, and/or mutants thereof, for use in the diagnosis, prevention and/or treatment of RIP2-kinase associated diseases. Moreover, the present invention provides methods of using said compounds, for instance as a medicine or diagnostic agent.

Structure-Activity Relationship of Heterocyclic P2Y14Receptor Antagonists: Removal of the Zwitterionic Character with Piperidine Bioisosteres

A known zwitterionic, heterocyclic P2Y14R antagonist 3a was substituted with diverse groups on the central phenyl and terminal piperidine moieties, following a computational selection process. The most potent analogues contained an uncharged piperidine bioisostere, prescreened in silico, while an aza-scan (central phenyl ring) reduced P2Y14R affinity. Piperidine amide 11, 3-aminopropynyl 19, and 5-(hydroxymethyl)isoxazol-3-yl) 29 congeners in the triazole series maintained moderate receptor affinity. Adaption of 5-(hydroxymethyl)isoxazol-3-yl gave the most potent naphthalene-containing (32; MRS4654; IC50, 15 nM) and less active phenylamide-containing (33) scaffolds. Thus, a zwitterion was nonessential for receptor binding, and molecular docking and dynamics probed the hydroxymethylisoxazole interaction with extracellular loops. Also, amidomethyl ester prodrugs were explored to reversibly block the conserved carboxylate group to provide neutral analogues, which were cleavable by liver esterase, and in vivo efficacy demonstrated. We have, in stages, converted zwitterionic antagonists into neutral molecules designed to produce potent P2Y14R antagonists for in vivo application.

PROTEIN KINASE INHIBITORS FOR PROMOTING LIVER REGENERATION OR REDUCING OR PREVENTING HEPATOCYTE DEATH

The invention relates to compounds of formula (I) which are inhibitors of MKK4 (mitogen-activated protein kinase kinase 4) and their use in promoting liver regeneration or reducing or preventing hepatocyte death. The compounds selectively inhibit protein kinase MKK4 over protein kinases JNK and MKK7. (I), wherein R x, R y , R z and R zz are selected from: a) R x and R y are F and R z and R zz are H; b) R x, R y and R zz are independently halogen and R z is H; c) R x R z and R zz are independently halogen and R y is H; and d) R x R y and R z are independently halogen and R zz is H

Exploration of Alternative Scaffolds for P2Y14Receptor Antagonists Containing a Biaryl Core

Various heteroaryl and bicyclo-aliphatic analogues of zwitterionic biaryl P2Y14 receptor (P2Y14R) antagonists were synthesized, and affinity was measured in P2Y14R-expressing Chinese hamster ovary cells by flow cytometry. Given this series' low water solubility, various polyethylene glycol derivatives of the distally binding piperidin-4-yl moiety of moderate affinity were synthesized. Rotation of previously identified 1,2,3-triazole attached to the central m-benzoic acid core (25) provided moderate affinity but not indole and benzimidazole substitution of the aryl-triazole. The corresponding P2Y14R region is predicted by homology modeling as a deep, sterically limited hydrophobic pocket, with the outward pointing piperidine moiety being the most flexible. Bicyclic-substituted piperidine ring derivatives of naphthalene antagonist 1, e.g., quinuclidine 17 (MRS4608, IC50 ≈ 20 nM at hP2Y14R/mP2Y14R), or of triazole 2, preserved affinity. Potent antagonists 1, 7a, 17, and 23 (10 mg/kg) protected in an ovalbumin/Aspergillus mouse asthma model, and PEG conjugate 12 reduced chronic pain. Thus, we expanded P2Y14R antagonist structure-activity relationship, introducing diverse physical-chemical properties.

Novel sulfamoylbenzoates as antifungal agents against Malassezia furfur

Novel polyfunctional arenesulfonamides as potential fungicides were prepared in eight steps from 3-amino-5-bromobenzoic acid. Among them, methyl 3-bromo-2-nitro-5-(N-phenylsulfamoyl)benzoate exhibiting significant cytotoxic activity against Malassezia fur

HETEROCYCLIC P2Y14 RECEPTOR ANTAGONISTS

Disclosed are compounds of formulas (I)-(IX) for treating or preventing a disease or disorder responsive to antagonism of a P2Y14R receptor agonist in a mammal in need thereof, wherein R1-R8, X, Y, Z, X', Y', Z', and A are

Design, synthesis and anti-inflammatory evaluation of 3-amide benzoic acid derivatives as novel P2Y14 receptor antagonists

The P2Y14 receptor (P2Y14R) plays a key role in the modulation of inflammatory process, but very few classes of antagonists have been reported. A series of 3-amide benzoic acid derivatives were identified as novel and potent P2Y

3-acylamino benzoic acid derivatives as well as preparation method and medical application thereof

The invention belongs to the field of medicinal chemistry and relates to 3-acylamino benzoic acid derivatives, pharmaceutical composition containing the compounds, a preparation method of the derivatives and an application of the derivatives as a therapeutic agent in the aspect of medical treatment, in particular to a medical application of the derivatives as a P2Y14 receptor antagonist.